MX2009012377A - Compuestos de arilamida pirimidona. - Google Patents
Compuestos de arilamida pirimidona.Info
- Publication number
- MX2009012377A MX2009012377A MX2009012377A MX2009012377A MX2009012377A MX 2009012377 A MX2009012377 A MX 2009012377A MX 2009012377 A MX2009012377 A MX 2009012377A MX 2009012377 A MX2009012377 A MX 2009012377A MX 2009012377 A MX2009012377 A MX 2009012377A
- Authority
- MX
- Mexico
- Prior art keywords
- group
- alkyl group
- atom
- hydrogen atom
- optionally substituted
- Prior art date
Links
- 150000008318 pyrimidones Chemical class 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000004754 (C2-C12) dialkylamino group Chemical group 0.000 abstract 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
Un derivado de pirimidona representado por la fórmula (I) o una de sus sales o uno de sus solvatos o uno de sus hidratos, en la que: X representa dos átomos de hidrógeno, un átomo de azufre, un átomo de oxígeno o un grupo alquilo C1-2 y un átomo de hidrógeno; Z representa un enlace, un átomo de oxígeno, un átomo de nitrógeno sustituido con un átomo de hidrógeno o un grupo alquilo C1-3, un átomo de azufre, un grupo metileno opcionalmente sustituido con uno o dos grupos elegidos entre un grupo alquilo C1-6 un grupo hidroxilo, un grupo alcoxi C1-6, un grupo alquilo C1-2 perhalogenado o un grupo amino; R1 representa un anillo de 2, 4 ó 5-pirimidina o un anillo de 4-piridina, estando el anillo opcionalmente sustituido con un grupo alquilo C1-6, un grupo alcoxi C1-6 o un átomo de halógeno; R2 representa un anillo de benceno, un anillo de naftaleno o un grupo bencilo; estando los anillos opcionalmente sustituidos con 1 a 4 sustituyentes elegidos entre un grupo alquilo C1-6, un grupo cicloalquilo C3-7, un grupo cicloalquil C3-7-alquilo C1-6, un átomo de halógeno, un grupo alquilo C1-2 perhalogenado, un grupo alquilo C1-3 halogenado, un grupo hidroxilo, un grupo heteroarilo opcionalmente sustituido con un grupo alquilo C1-6, un grupo cicloalquilo C3-7, un grupo cicloalquil C3-7-alquilo-C1-6, un grupo alcoxi C1-6 opcionalmente sustituido con un grupo cicloalquilo C3-5, un grupo alcoxi C1-2 perhalogenado, un grupo alquil C1-6-sulfonilo, un grupo nitro, ciano, amino, monoalquil C1-6-amino o un grupo dialquil C2-12-amino, un grupo acetoxi o un grupo aminosulfonilo; R3 representa un átomo de hidrógeno, un grupo alquilo C1-6 o un átomo de halógeno; R4 representa un átomo de hidrógeno o un grupo alquilo C1-6; R5 representa un átomo de hidrógeno o un grupo alquilo C1-6; R6 representa un átomo de hidrógeno o un grupo alquilo C1-6; R7 representa un átomo de hidrógeno o un grupo alquilo C1-6; n representa de 0 a 3; y m representa 1, en forma de una base libre o de una sal de adición con un ácido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07290626A EP1992625A1 (en) | 2007-05-16 | 2007-05-16 | Arylamide pyrimidone compounds |
| PCT/IB2008/002458 WO2008155670A2 (en) | 2007-05-16 | 2008-05-14 | Arylamide pyrimidone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009012377A true MX2009012377A (es) | 2009-12-03 |
Family
ID=38596326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009012377A MX2009012377A (es) | 2007-05-16 | 2008-05-14 | Compuestos de arilamida pirimidona. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8598187B2 (es) |
| EP (2) | EP1992625A1 (es) |
| JP (1) | JP5508257B2 (es) |
| KR (1) | KR20100016511A (es) |
| CN (1) | CN101679379A (es) |
| AR (1) | AR066604A1 (es) |
| AU (1) | AU2008264902A1 (es) |
| BR (1) | BRPI0811597A2 (es) |
| CA (1) | CA2687156A1 (es) |
| EA (1) | EA200971063A1 (es) |
| IL (1) | IL201625A0 (es) |
| MX (1) | MX2009012377A (es) |
| NZ (1) | NZ581164A (es) |
| TW (1) | TW200948802A (es) |
| WO (1) | WO2008155670A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2961746B1 (en) | 2013-02-28 | 2018-01-03 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
| AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| WO2015155738A2 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4145423A (en) | 1976-02-10 | 1979-03-20 | Rhone-Poulenc Industries | Pyrimidinyl-1,2-dithiole compounds and anti-bilharzia compositions thereof |
| US5629322A (en) | 1994-11-15 | 1997-05-13 | Merck & Co., Inc. | Cyclic amidine analogs as inhibitors of nitric oxide synthase |
| KR100581199B1 (ko) | 1998-06-19 | 2006-05-17 | 카이론 코포레이션 | 글리코겐 신타제 키나제 3의 억제제 |
| TWI241298B (en) * | 1998-09-25 | 2005-10-11 | Mitsubishi Chem Corp | Pyrimidone derivatives |
| CA2457952C (en) | 2001-09-21 | 2009-11-10 | Sanofi-Synthelabo | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h) one derivatives for neurodegenerative disorders |
| CA2510170C (en) | 2002-12-16 | 2011-05-24 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
| EP1454909B1 (en) * | 2003-03-07 | 2008-08-20 | Sanofi Aventis | 8'-pyridinyl-dihydrospiro- (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one derivatives and their use against neurodegenerative diseases |
| AR043486A1 (es) | 2003-03-07 | 2005-08-03 | Sanofi Aventis | Derivados de 2-(diaza-biciclo-alquil)-pirimidona |
| EP1790649A1 (en) | 2005-11-21 | 2007-05-30 | Sanofi-Aventis | Substituted bicyclic pyrimidone derivatives |
-
2007
- 2007-05-16 EP EP07290626A patent/EP1992625A1/en not_active Withdrawn
-
2008
- 2008-05-14 MX MX2009012377A patent/MX2009012377A/es not_active Application Discontinuation
- 2008-05-14 EP EP08807123.8A patent/EP2160388B1/en active Active
- 2008-05-14 WO PCT/IB2008/002458 patent/WO2008155670A2/en not_active Ceased
- 2008-05-14 EA EA200971063A patent/EA200971063A1/ru unknown
- 2008-05-14 BR BRPI0811597A patent/BRPI0811597A2/pt not_active IP Right Cessation
- 2008-05-14 NZ NZ581164A patent/NZ581164A/en not_active IP Right Cessation
- 2008-05-14 CN CN200880016007A patent/CN101679379A/zh active Pending
- 2008-05-14 KR KR1020097023695A patent/KR20100016511A/ko not_active Withdrawn
- 2008-05-14 AU AU2008264902A patent/AU2008264902A1/en not_active Abandoned
- 2008-05-14 JP JP2010508005A patent/JP5508257B2/ja active Active
- 2008-05-14 CA CA002687156A patent/CA2687156A1/en not_active Abandoned
- 2008-05-16 AR ARP080102085A patent/AR066604A1/es unknown
- 2008-05-16 TW TW097118157A patent/TW200948802A/zh unknown
-
2009
- 2009-10-19 IL IL201625A patent/IL201625A0/en unknown
- 2009-10-27 US US12/606,662 patent/US8598187B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010526867A (ja) | 2010-08-05 |
| CA2687156A1 (en) | 2008-12-24 |
| TW200948802A (en) | 2009-12-01 |
| CN101679379A (zh) | 2010-03-24 |
| BRPI0811597A2 (pt) | 2017-05-02 |
| JP5508257B2 (ja) | 2014-05-28 |
| KR20100016511A (ko) | 2010-02-12 |
| US20100087461A1 (en) | 2010-04-08 |
| EP1992625A1 (en) | 2008-11-19 |
| WO2008155670A3 (en) | 2009-04-09 |
| AU2008264902A1 (en) | 2008-12-24 |
| IL201625A0 (en) | 2010-05-31 |
| NZ581164A (en) | 2011-11-25 |
| US8598187B2 (en) | 2013-12-03 |
| EP2160388B1 (en) | 2013-12-18 |
| EA200971063A1 (ru) | 2010-06-30 |
| EP2160388A2 (en) | 2010-03-10 |
| WO2008155670A2 (en) | 2008-12-24 |
| AR066604A1 (es) | 2009-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009012377A (es) | Compuestos de arilamida pirimidona. | |
| MX2010008361A (es) | Derivados de arilamida oxazepinopirimidona sustituidos. | |
| MX2009012383A (es) | Derivados de arilamida pirimidona para el tratamiento de enfermedades neurodegenerativas. | |
| MX2009012380A (es) | Compuestos de heteroarilamida pirimidona. | |
| CY1109345T1 (el) | ΠΑΡΑΓΩΓΑ ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 8-ΥΠΕΡΦΘΟΡΟΑΛΚΥΛΟ-6,7,8,9-ΤΕΤΡΑΫΔΡΟΠΥΡΙΜΙΔΟ (1,2-a) ΠΥΡΙΜΙΔΙΝ-4-ΟΝΗΣ | |
| AR072225A1 (es) | Derivados de alquil pirimidin-4-ona sustituidos y procedimiento para prepararlos | |
| PH12012501711A1 (en) | [5,6] heterocyclic compound | |
| MX2010008362A (es) | Derivados de heteroarilamida diazepinopirimidona sustituidos. | |
| MX2010008360A (es) | Derivados de oxazepinopirimidona heteroarilamida sustituidos. | |
| MXPA05008619A (es) | Derivados novedosos de 2-piridincarboxamida. | |
| EA201170093A1 (ru) | Замещенные n-оксидпиразиновые производные | |
| EA201170099A1 (ru) | Замещенные пиримидин-4-оновые производные | |
| GEP201706728B (en) | Noxious organism control agent | |
| WO2009156861A3 (en) | Substituted pyrimidone derivatives | |
| HRP20070328T3 (hr) | SUPSTITUIRANI 8'-PIRI(MI)DINILDIHIDROSPIRO[CIKLO-ALKLIAMIN]PIRIMIDO[1,2-a]PIRIMIDIN-6-ONSKI DERIVATI | |
| MY169179A (en) | Novel piperidine compound or salt thereof | |
| MX2010008363A (es) | Derivados de arilamida diazepinopirimidona sustituidos para el tratamiento de enfermedades neurodegenerativas causadas por la actividad anormal de gsk3-beta. | |
| TNSN06203A1 (en) | Derivatives of n- (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity | |
| EA200971060A1 (ru) | Гетероариламидные пиримидоновые производные | |
| TH106957A (th) | อนุพันธ์เอริลเอไมด์ ไพริมิโดน | |
| TH106958A (th) | สารประกอบเอริลเอไมด์ ไพริมิโดน | |
| TH104960A (th) | อนุพันธ์ซับสทิทิวเต็ดอะริลลาไมด์ออกซาเซพิโนไพริมิโดน | |
| EA200970120A1 (ru) | Новые производные 5-тиоксилопиранозы | |
| MX2007005892A (es) | Derivados de acido piridonacarboxilico novedosos y sales de los mismos. | |
| ATE500243T1 (de) | Carbonsäureamidverbindung und deren verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FA | Abandonment or withdrawal |